Abstract-HIMF (hypoxia-induced mitogenic factor) is a secreted proinflammatory cytokine with a critical role in cardiac hypertrophy development. Loss of HIMF attenuates transverse aortic constriction-induced cardiac hypertrophy and fibrosis, but the underlying mechanisms are unknown. We show that IL (interleukin)-6 production increases following transverse aortic constriction in wild-type mice; this effect is inhibited in HIMF gene knockout (Himf
C ardiac hypertrophy describes adverse cardiac remodeling typically accompanied with cardiomyocyte hypertrophy, fibrosis, and myocyte loss. Cardiac hypertrophy is most commonly caused by hypertension; although the remodeling process initially confers protection to the heart as a compensatory mechanism, persistent cardiac hypertrophy leads to declined myocardium function and heart failure. 1 Cardiac remodeling involves several molecular pathways, including neurohormonal activation via the sympathoadrenomedullary and renin-angiotensin-aldosterone systems, oxidative stress, and altered energy metabolism: all these pathways can converge on inflammation. Chronic inflammation is thus a prominent feature in cardiac hypertrophy and leads to myocyte hypertrophy and fibrosis by stimulating cytokine release. 2, 3 HIMF (hypoxia-induced mitogenic factor), also known as found in inflammatory zone (FIZZ1/RELMα), is a cytokine-like protein. [4] [5] [6] HIMF induction has been originally linked to lung pathological conditions, particularly in hypoxia-induced pulmonary hypertension. 6, 7 Our recent work demonstrated that HIMF is upregulated in hearts and has a central role in pressure overload-induced cardiac hypertrophy. 8 HIMF ablation largely attenuated cardiac hypertrophy in mice subjected to transverse aortic constriction (TAC), which is partially attributed to the direct effect of HIMF on inducing cardiomyocyte hypertrophy. This is the first study showing the role of HIMF in cardiac hypertrophy development, but the underlying mechanisms are poorly understood. Here, HIMF deficiency can also attenuate cardiac fibrosis and diastolic dysfunction in TAC mice. 8 While activated myofibroblasts are the main effector cells in cardiac fibrosis in hypertrophy, 9, 10 HIMF expression in cardiac fibroblasts (CFs) and the direct role of HIMF in myofibroblast formation remain unknown.
A recent study demonstrated that HIMF induces lung vascular inflammation and perivascular fibrosis by increasing IL (interleukin)-6 in macrophages and lung resident cells. 11 IL-6 is a pleiotropic cytokine which can be produced by cardiac myocytes. 12 Previous studies suggested the important role of IL-6 in the pathogenesis of cardiac hypertrophy. [13] [14] [15] Supporting evidence includes infusion of IL-6 induced left ventricular (LV) hypertrophy in rats via mechanisms unrelated to increased blood pressure, 13 and IL-6 deletion attenuated Ang II (angiotensin II) and norepinephrine-induced cardiac hypertrophy in mice. 14, 15 A recent study demonstrated that IL-6 ablation ameliorates TAC-induced LV hypertrophy and fibrosis in mice. 16 This mouse model closely represents pressure overload-induced LV hypertrophy in humans. Here, IL-6 had a direct effect on inducing cardiac myocyte hypertrophy. The results from this study led to the conclusion that IL-6 signaling is essential for the development of pressure overload-induced cardiac hypertrophy. 16 Interestingly, IL-6 can also be produced in fibroblasts and causes cardiomyocyte hypertrophy through a paracrine effect, 17 suggesting that IL-6 mediates the crosstalk between cardiomyocytes and fibroblasts in cardiac hypertrophy. In macrophages and lung resident cells, HIMF stimulates IL-6 production through a HIF (hypoxia-induced factor)-1α-dependent mechanism, 11 and HIF-1α involves in HIMF-induced cardiac hypertrophy. 8 In view of these findings, we hypothesized that IL-6 is a downstream signal of HIMF that mediates cardiac hypertrophy development.
Our present study explored the effects of HIMF on IL-6 production in pressure overload-induced LV hypertrophy in HIMF knockout (himf
−/−
) and TAC-induced hypertrophic mice. We also investigated the direct effects of HIMF on IL-6 production in cardiomyocytes, and the possible role of IL-6 in mediating HIMF-induced cardiac myocyte hypertrophy. Finally, we studied the effects of HIMF on CF proliferation, migration and myofibroblast differentiation, and the involvement of IL-6 signaling.
Methods
The data that support the findings of this study are available from the author Gang Wang (wangg@szu.edu.cn) on reasonable request. Detailed methods are available in the online-only Data Supplement materials and methods section.
Animals
All the animals used in this study were purchased from the Animal Center of Guangdong Province, China. All animal protocols were approved by the Institutional Care and Ethical Committee of Shenzhen University and followed the procedures outlined in the Guide for the Care and Use of Laboratory Animals (National Institutes of Health publication No. 85-23, revised 1996).
Generation of the HIMF-Knockout (Himf −/− ) Mice
Himf −/− mice were generated via the CRISP/Cas9 system as previously reported. 8 All mice functionally characterized in this study were aged 6 to 8 weeks, from F2 and F3 generations and genotyped by polymerase chain reaction, followed by sequence analysis.
Transverse Aortic Constriction
C57BL/6J male mice (7-8 weeks, 18-24 g) were randomly divided into 4 groups: (1) sham Himf wild-type (wt), (2) sham Himf
, and (4) TAC Himf wt. The TAC model was produced as previously described.
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Neonatal Rat Ventricular Myocyte and Neonatal Rat CFs Culture
Neonatal rat ventricular myocyte (NRVMs)/CFs were isolated and cultured from 1 to 2-day-old Sprague-Dawley rats, as previously described.
19
Statistical Analysis
Data are presented as the means±SEM. Statistical analyses between groups were performed by unpaired Student t test. Differences among multiple groups were tested by 1-way ANOVA, and levels of significance were determined using Bonferroni multiple comparisons test in GraphPad Prism (GraphPad Prism 6 Software Inc, San Diego, CA). In all cases, a P<0.05 was considered statistically significant.
Results
HIMF Ablation Decreases IL-6 Production and Attenuates Cardiac Hypertrophy and Fibrosis in TAC Mice
We first examined the effects of HIMF on IL-6 production during cardiac hypertrophy in sham and TAC wt and Himf −/− mice. We found a significant increase in cell size and fibrosis area in heart slices, and heart weight/body weight ratio from wt-TAC mice compared with all other groups ( Figure 1A and 1B). Consistently, the protein levels of the cardiac hypertrophy markers ANP (atrial natriuretic peptide) and β-MHC (myosin heavy chain-beta), and fibrosis markers αSMA (alpha smooth muscle actin) and Col1α2 (collagen type 1α2) were notably increased in wt-TAC mice compared with all other groups ( Figure 1C) . The results confirm the pathogenesis of cardiac hypertrophy and fibrosis in TAC mice and HIMF ablation attenuated the pathological remodeling.
The concentrations of IL-6 in the serum of wt-TAC mice were remarkably increased compared with wt-Sham mice ( Figure 1D ). Immunostaining for IL-6 confirmed that IL-6 expression significantly increased in cardiac myocytes and CFs in heart slices from wt-TAC mice compared with wt-Sham mice ( Figure 1E ). Loss of Himf largely decreased IL-6 concentrations in the serum ( Figure 1D ) and in cardiomyocytes and CFs in heart slices from TAC mice ( Figure 1E ). These results suggest that IL-6 is upregulated by HIMF during TAC and may participate in cardiac hypertrophy and fibrosis.
IL-6 Mediates HIMF-Induced Cardiomyocyte Hypertrophy in NRVMs and Adult Mouse VMs
We next explored the direct link between HIMF upregulation and IL-6 production in cultured NRVMs as well as adult mouse VMs (AMVMs). We found that HIMF overexpression significantly increased IL-6 production in NRVMs, from 51.6±5.6 pg/mL in control cells to 107.1±17.5 pg/mL in HIMFoverexpressing cells (P<0.05; Figure 2A ). HIMF had similar effect on IL-6 production in AMVMs (P<0.05; Figure 2A ). We then investigated the contribution of IL-6 to HIMF-induced cardiomyocyte hypertrophy by suppressing IL-6 via antibodybased neutralization. We found no effect of blocking IL-6 on 
HIMF Induces Fibroblast Migration and Proliferation, and Myofibroblast Differentiation Through a Cardiomyocyte-Fibroblast Paracrine Effect
Thus far, our in vivo data have shown that Himf −/− attenuates cardiac fibrosis in mouse hearts following TAC ( Figure 1A ), suggesting that upregulated HIMF participates in cardiac fibrosis during the development of hypertrophy. To address how HIMF exerts its antifibrosis role, we first examined whether HIMF is upregulated in CFs by hypertrophic stimulation. By immunostaining, we found that HIMF expression did not significantly increase in CFs from TAC mouse heart slices compared with sham slices ( Figure 3A ). By contrast, HIMF expression remarkably increased in the myocardium of wt TAC compared with sham mice ( Figure 3A ). Comparing HIMF protein levels in cardiomyocytes and CFs confirmed that there was minimal HIMF expression in fibroblasts ( Figure  S1 in the online-only Data Supplement).
Stimulating the cultured NRVMs with the prohypertrophic factor, phenylephrine increased HIMF expression ( Figure 3B , upper), as shown in our previous study. 8 Conversely, we observed no effect of phenylephrine stimulation on HIMF expression in CFs ( Figure 3B, upper) . Furthermore, we saw no increase in HIMF on the stimulation of Ang II and TGF (transforming growth factor)-β, which prominently stimulate cardiac fibrosis ( Figure 3B, upper) . Even hypoxia, a potent stimulator of HIMF in the lung 7 and cardiac myocytes, 8 could not stimulate HIMF production in CFs ( Figure 3B , lower). These data indicate that HIMF expression cannot be stimulated in CFs during hypertrophy.
We next addressed why HIMF KO attenuates cardiac fibrosis. Given HIMF is a secretory protein, we hypothesized that HIMF can be secreted to the ECM (extracellular matrix) during cardiac hypertrophy and induces cardiac fibrosis via a paracrine effect. To prove this hypothesis, we stimulated CFs with the conditioned culture medium collected from cardiomyocytes infected with GFP (Ad-GFP) or HIMF-carrying adenovirus (Ad-HIMF). The cardiomyocytes were incubated in culture medium with Ad-GFP or Ad-HIMF for 4 hours and then the medium was washed out and replaced with adenovirus-free medium. After 48 hours, the culture medium was collected. The protein level of HIMF in cardiomyocytes infected with Ad-HIMF increased compared with Ad-GFP ( Figure S2 ). As expected, the concentration of HIMF in Ad-HIMF conditioned medium (9.86±0.74 ng/mL) was much higher than that in Ad-GFP control medium (1.07±0.16 ng/mL; P<0.01; Figure 3C ). Treating the fibroblasts with the conditioned medium for 24 hours markedly increased fibroblast migration (indexed by the wound-healing assay, Figure 3D ) and proliferation (indexed by the cell viability, Figure 3E ) compared with Ad-GFP control medium. Furthermore, Col1α2 and αSMA expression in fibroblasts increased in Ad-HIMF conditioned medium relative to Ad-GFP control medium ( Figure 3F ), indicating enhanced myofibroblast differentiation.
We confirmed the direct effects of HIMF on fibroblasts by stimulating the cells with 10 to 100 ng/mL rHIMF (recombinant HIMF). We found that rHIMF induced fibroblast proliferation (indicated by increased cell viability, Figure 4A ) and myofibroblast differentiation (indicated by increased expression of Col1α2 and αSMA, Figure 4B ) in a dose-dependent manner. rHIMF significantly increased αSMA and Col1α2 expression at concentrations ranging from 25 to 100 ng/mL, peaking at a concentration of 50 ng/mL ( Figure 4A and 4B) . Furthermore, wound-healing assay indicated that rHIMF (50 ng/mL) significantly increased fibroblast migration ( Figure 4C ). Because the role of HIMF in inducing cardiac fibrosis in in vivo animal model was observed in mice, the effects of rHIMF on the activation of CFs were also examined in CFs from mice. We found that rHIMF (50 ng/mL) had similar effects on the properties of CFs from mice, where fibroblast proliferation ( Figure 4D ) and myofibroblast differentiation ( Figure 4E ), as well as fibroblast migration ( Figure 4F ) were increased. Furthermore, the responses to rHIMF in CFs from wt mice were comparable to CFs from Himf −/− mice ( Figure 4D through 4F ). These data collectively indicate that HIMF can activate CFs through a cardiomyocyte-to-fibroblast paracrine signaling mechanism.
IL-6 Participates in HIMF-Induced Fibroblast Proliferation and Migration, and Myofibroblast Differentiation
Next, we explored whether HIMF induces cardiac fibrosis via IL-6. We found that rHIMF treatment (50 ng/mL, 24 hours) markedly increased IL-6 production in CFs, from 92.6±8.9 pg/ mL in control group to 188.8±35.2 pg/mL in rHIMF-stimulated cells ( Figure 5A ). Pretreating the rHIMF-stimulated fibroblasts with an anti-IL-6 antibody (rHIMF+anti-IL-6) suppressed Col1α2 and αSMA expression ( Figure 5B ), migration ( Figure 5D ) and cell proliferation ( Figure 5F ) compared with IgG treatment (rHIMF+IgG). Similar effects of anti-IL-6 antibody on Col1α2 and αSMA expression ( Figure 5C ), migration ( Figure 5E ), and cell proliferation ( Figure 5F ) were observed in rHIMF-stimulated CFs from mice. These data indicate that IL-6 has a critical role in HIMF-induced fibroblast activation.
Activation of MAPK and CaMKII-STAT3
Pathways by IL-6 Contributes to HIMF-Induced Cardiomyocyte Hypertrophy IL-6 interacts with its receptor gp130 to activate the signal transducer and activator of transcription (STAT)1, STAT3, and . Extracellular rHIMF (recombinant hypoxia-induced mitogenic factor) induces the proliferation, differentiation, and migration of cardiac fibroblasts (CFs). A, Cell proliferation evaluated by colorimetric BrdU assay in neonatal rat CFs stimulated with 0-100 ng/mL rHIMF for 24 h. N=6/group. *P<0.05 vs without rHIMF group. B, Representative immunoblots and pool data of Col1α2 (collagen type 1α2) and αSMA (alpha smooth muscle actin) protein levels in rat CFs stimulated with rHIMF (0 to 100 ng/mL) for 24 h (N=3/group). *P<0.05 and **P<0.01 vs without rHIMF group. C, Representative images of wound-healing migration assay in rat CFs were captured at 0 and 24 h after rHIMF (50 ng/mL) stimulation. Scale bar, 100 µm. The relative speed of fibroblast migration was measured by its mean linear movement over wound edges at 24 h. N=6/group. *P<0.05 and **P<0.01 vs Ctrl. D-F, Cell proliferation evaluated by colorimetric BrdU assay (D), representative immunoblots and statistics of Col1α2 and αSMA protein levels (E), and, representative images of wound-healing migration assay and its quantification at 0 and 24 h (F) in the wild type (wt) and HIMF-knockout (himf . A, Average of secreted IL-6 levels in the conditioned medium with or without rHIMF (recombinant HIMF) treatment (50 ng/mL, 24 h) in CFs isolated from neonatal rats and mice (N=6/group). CFs were pretreated for 30 min with anti-IL-6 antibody (0.1 µg/mL) or IgG Isotype (0.1 µg/mL) as a control, followed by rHIMF (50 ng/mL) stimulation for 24 h. N=6/group. B and C, Representative immunoblots and statistics of Col1α2 (collagen type 1α2) and αSMA (alpha smooth muscle actin) protein levels in the CFs isolated from rats (B) or mice (C) groups (N=4/group). D and E, Representative images of wound-healing (Continued ) MAPK (mitogen-activated protein kinase) cascades. 20, 21 Our previous study showed that HIMF activates the ERK (extracellular regulated MAP kinase), JNK (c-Jun NH2-terminal kinase), and p38 cascades of the MAPK signaling pathway during cardiac hypertrophy. 8 Here, we confirmed these previous findings in HIMF-overexpressing cardiomyocytes ( Figure 6A ). Furthermore, we found that anti-IL-6 blockade prevented HIMF-overexpression-induced activation of MAPKs ( Figure 6A ), indicating that IL-6 contributes to HIMF-mediated MAPK activation.
A recent study demonstrated that IL-6-activates CaMKII (Ca 2+ /calmodulin-dependent protein kinase II) and STAT3 pathways in cardiac hypertrophy. 16 We found that HIMF overexpression increases CaMKII and STAT3 phosphorylation ( Figure 6B ). Exposure to the anti-IL-6 antibody prevented CaMKII and STAT3 activation ( Figure 6B ). Furthermore specific inhibition of CaMKII with KN93 (2.5 µmol/L, 30 minutes, Figure S3A ) or STAT3 with S3I-201 (50 µmol/L, 30 minutes, Figure S3B ) largely attenuated cardiomyocyte hypertrophy (decreased the ANP and β-MHC expression shown in Figure S3A and S3B, and cell surface area shown in Figure  S3C ) in HIMF-overexpressing cells. KN93 also suppressed STAT3 phosphorylation ( Figure S3A ), whereas S3I-201 did not suppress CaMKII activation ( Figure S3B ). Neither KN93 nor S3I-201 affected HIMF expression ( Figure S3A and S3B ).
IL-6-MAPK and IL-6-CaMKII-STAT3 Pathways Participate in HIMF-Induced Fibroblast Activation
The MAPK pathway is important for activating fibroblasts. 2, 22 In this study, we found that rHIMF profoundly increases ERK, JNK, and p38 phosphorylation at 15 minutes, and this effect could be inhibited on exposure to an anti-IL-6 antibody ( Figure 6C ). These results indicate that the IL-6-MAPK pathway contributes to HIMF-induced fibroblast activation. Although evidence indicates that IL-6 activates the CaMKII-STAT3 pathway in cardiac myocytes, it remains unknown whether IL-6 activates the CaMKII-STAT3 pathway in CFs and the potential role of this pathway in fibroblast activation. Here, we found that rHIMF significantly increased the CaMKII and STAT3 phosphorylation levels ( Figure 6D ). Anti-IL-6 antibody largely inhibited this activation in response to rHIMF stimulation ( Figure 6D ). In addition, the CaMKII-specific inhibitor KN93 prevented CaMKII and STAT3 activation ( Figure S4A) , and the STAT3-specific inhibitor S3I-201 inhibited the STAT3 but not CaMKII phosphorylation ( Figure S4B ) in rHIMFstimulated CFs. Both KN93 and S3I-201 decreased the protein levels of Colα2 and αSMA ( Figure S4A and S4B), fibroblast migration ( Figure S5A ) and proliferation ( Figure S5B ) on rHIMF stimulation. Thus, HIMF can also activate the CaMKII-STAT3 pathway through IL-6, leading to CF activation.
We had similar findings in CaMKII-STAT3 pathway in pressure overload-induced cardiac hypertrophy in Himf −/− mice, where CaMKII and STAT3 phosphorylation levels were markedly increased in wt-TAC mouse hearts relative to sham, and ablation of HIMF inhibited CaMKII and STAT3 activation ( Figure 6E ). The change in CaMKII-STAT3 pathway is consistent with perturbed IL-6 production ( Figure 1D ). These results support that IL-6 activates the CaMKII-STAT3 pathway and contributes to HIMF-induced cardiac hypertrophy.
Discussion
The novel findings from this study are as follows: (1) HIMF induces IL-6 production in cardiomyocytes, contributing to HIMF-induced cardiomyocyte hypertrophy; (2) HIMF is not stimulated in fibroblasts during cardiac hypertrophy. HIMF induces cardiac fibrosis by stimulating fibroblast proliferation and migration, and myofibroblast differentiation through a cardiomyocyte-to-fibroblast paracrine effect; (3) HIMF stimulates IL-6 production in fibroblasts, which subsequently activates fibroblasts; and (4) IL-6 activates the MAPK and CaMKII-STAT3 signaling pathways in cardiomyocytes and fibroblasts, leading to cardiomyocyte hypertrophy and fibroblast activation in response to HIMF stimulation. In summary, HIMF and IL-6 mediate the crosstalk between cardiomyocytes and fibroblasts to promote cardiac hypertrophy and fibrosis.
HIMF Induces Cardiac Fibrosis Through a Cardiomyocyte-to-Fibroblast Paracrine Effect
Cardiac fibrosis is a prominent pathological change of pressure overload-induced LV remodeling that results in deterioration of LV compliance and development of diastolic dysfunction. 23 During this process, cardiac fibroblasts become activated and differentiate to myofibroblasts to secrete high levels of proinflammatory and profibrotic paracrine factors as well as abnormal ECM proteins, which promote fibroblast proliferation ensuing in cardiac fibrosis. Cardiac fibroblasts and cardiomyocytes are in close proximity, and the communication between them are critical for maintaining cardiac function in normal heart and promoting cardiac dysfunction in the context of diseased status. TGF-β1 and Ang II signaling pathways are the 2 most well-studied pathways affecting myocyte-fibroblast communication through paracrine effect in the context of cardiac fibrosis. They are both expressed in cardiomyocytes and fibroblasts and recognized as therapeutic targets for the treatment of cardiac fibrosis. Strategies inhibiting Ang II signaling pathways, including angiotensin-converting enzyme inhibitor and Ang II receptor antagonists have been applied in clinical treatment of cardiovascular disease and have beneficial effects on cardiac fibrosis. Nevertheless, new therapeutic strategies against cardiac fibrosis are highly expected because of the complications of the development of cardiac fibrosis. In this study, we found that HIMF cannot be stimulated in CFs by hypertrophic stimuli, which is in stark contrast to the remarkable increase in HIMF levels in adjacent cardiomyocytes. However, CFs are activated by exogenous HIMF stimulation. Particularly, the conditioned medium of cardiomyocytes overexpressing HIMF activates CFs. Therefore, our data provide the first evidence that cardiomyocytes participate in the pathogenesis of cardiac fibrosis by secreting HIMF to activate adjacent CFs through a paracrine effect. Moreover, the findings indicate HIMF is a Figure 5 Continued. assay (left) captured at 0 and 24 h after rHIMF and anti-IL-6 stimulation in rat (D) and mouse (E) CFs. Scale bar, 100 µm. The relative speed of CFs migration (right) was measured by as its mean linear movement over wound edges at 24 h (N=6/group). F, Cell proliferation was evaluated by colorimetric BrdU assay in rat or mouse CFs. N=6/group. *P<0.05 and **P<0.01 vs Ctrl+IgG group. #P<0.05 and ##P<0.01 vs rHIMF+IgG group.
†P<0.05 and ‡P<0.01 vs Ctrl+anti-IL-6 group.
potential therapeutic target in the treatment of cardiac fibrosis during the development of cardiac hypertrophy. Of note, HIMF production in cardiomyocytes is unrelated to Ang II as reported in our previous study, suggesting therapy against HIMF may have a synergistic effect with therapy against Ang II signaling in the treatment of cardiac fibrosis.
IL-6 Plays a Central Role in HIMF-Induced Cardiomyocyte Hypertrophy and Fibrosis
IL-6 is a soluble mediator with pleiotropic effects on inflammation, the immune response, and hematopoiesis. 24 Almost all stromal cells and cells of the immune system produce IL-6, but it can also be stimulated in cardiomyocytes.
2 IL-6 is produced in various cardiovascular diseases. 25, 26 Although the essential role of IL-6 in the pathogenesis of cardiac hypertrophy has been shown in previous studies, 16, 27 the mechanisms promoting IL-6 production are complicated and not completely understood. In this study, we found that HIMF ablation largely inhibited IL-6 production in the hearts of TAC mice. In cultured cardiomyocytes, HIMF overexpression stimulates IL-6 production and IL-6 blockade, prevented HIMF overexpression-induced cardiomyocyte hypertrophy. Therefore, we conclude that HIMF is an important upstream stimulator for IL-6 production, and IL-6 is largely responsible for HIMF-induced cardiac hypertrophy.
Our histological data demonstrate that IL-6 production is significantly increased in CFs on TAC injury, indicating that CFs are one of the major sources of IL-6 production in cardiac hypertrophy. Although HIMF cannot be produced in CFs, exogenously applied rHIMF or conditioned medium of cardiomyocytes overexpressing HIMF stimulates IL-6 production in CFs. HIMF deficiency markedly decreased IL-6 production in CFs in TAC mice. Therefore, IL-6 also contributes to HIMF-induced cardiac fibrosis. Interestingly, IL-6 as a secretary cytokine can effect on cardiomyocytes and fibroblasts through both autocrine and paracrine effect. IL-6 produced by cardiomyocytes induces cardiomyocyte hypertrophy through autocrine effect and CF activation through a retrograde mechanism involving paracrine myocyte-to-fibroblast effect. Likewise, IL-6 produced by CFs can also induce cardiomyocyte hypertrophy through a fibroblast-to-myocyte paracrine effect in addition to activate CFs through an autocrine effect. Therefore, both HIMF and IL-6 mediate the crosstalk between cardiomyocytes and CFs, promoting cardiac hypertrophy and fibrosis.
In our previous study, we found Ca 2+ -dependent and HIF-1α signalings contribute to HIMF-induced cardiomyocyte hypertrophy. It has been suggested that Ca 2+ regulates the expression of IL-6 in skeletal muscle, possibly through the Ca 2+ -dependent calcineurin, p38 MAPK, and CaMKII pathways. [28] [29] [30] IL-6 production has also been linked to the activation of HIF-1α in lung. 11 The activated signaling pathways appear to converge to IL-6 production ( Figure 6F ). Therefore, we propose IL-6 plays a central role in HIMF-induced cardiomyocyte hypertrophy and fibrosis.
MAPK and CaMKII-STAT3 Pathways Are Involved in HIMF-IL-6 Signaling in Cardiomyocytes and Fibroblasts
IL-6 interacts with its receptor gp130 to activate the STAT1, STAT3, and the MAPK signaling cascades. STAT3, the major isoform of STAT family in cardiac myocytes, and MAPK pathway have an important role in the development of cardiac hypertrophy, as well as fibrosis. A recent study demonstrated that IL-6 can also activate CaMKII, contributing to STAT3 activation and consequent cardiomyocyte hypertrophy. Our previous study demonstrated that HIMF upregulation in cardiac hypertrophy activates MAPK cascades, including ERK, JNK, and p38. Our current findings indicate that IL-6 contributes to the activation of the MAPK pathway in HIMF-induced cardiac hypertrophy. Furthermore, we found that HIMF activates CaMKII and subsequently STAT3 by stimulating IL-6 production. The data confirm MAPK and CaMKII-STAT3 are downstream signaling pathways of IL-6 in HIMF-induced cardiac hypertrophy ( Figure 6F ). In CFs, IL-6 also has an important role in HIMF-induced activation of the MAPK pathway, and IL-6 blockade inhibited MAPK activation and CFs activation. Although IL-6 activates CaMKII-STAT3 pathway in cardiomyocytes, it is unknown whether IL-6 can activate this pathway in fibroblasts and the nature of its role in fibroblast activation. We found that HIMF increases CaMKII and STAT3 phosphorylation levels in fibroblasts, and this effect was prevented during IL-6 blockade. Furthermore, inhibiting CaMKII and STAT3 inhibited fibroblast activation. These findings provide the first evidence that IL-6-CaMKII-STAT3 pathway participates in fibroblast activation, resulting in cardiac fibrosis ( Figure 6F ). Because calcineurin, p38 MAPK, and CaMKII pathways are linked to IL-6 production, 30 they may also serve as a positive feedback of HIMF-induced IL-6 production ( Figure 6F ).
Our previous 8 and the present study ( Figure S6 ) demonstrated HIMF expression is upregulated in response to prohypertrophic stimuli. However, the molecular machinery controlling HIMF expression remains poorly understood. Previous studies have suggested that HIMF expression is regulated by the transcription factor of HIF-1α. 31 However, in another study, it shows that HIF-1α is not essential for HIMF production in lung by using HIF-1α deficient mice. 11 The function of HIMF has also been linked to the activation of transcription factor STAT. 32 In this study, we explored the possible role of HIF-1α and STAT3 in HIMF production but failed to find they are linked to HIMF production in response to phenylephrine stimulation ( Figures S6 and S7) . That the mechanisms underlying HIMF dysregulation in cardiac hypertrophy remain unknown is a limitation of this study and warrants future study.
Perspectives
Progressive fibrosis causes stiffening of the cardiac tissue and affects conduction of electrical impulses, leading to heart failures in a broad range of cardiac conditions. Our findings identify a novel paracrine myocyte-to-fibroblast HIMF signaling mechanism for CF activation and cardiac fibrosis and shed new light on the important issue of the therapeutic role of HIMF inhibition in cardiac fibrosis in cardiac hypertrophy and heart failure. Because HIMF can be stimulated by hypoxia and inflammation, it may be induced in other myocardial diseases. Indeed, our preliminary experiments show HIMF is upregulated in myocardial infarction (data not shown) and may involve in fibrogenic remodeling. The therapeutic strategy based on HIMF inhibition may be extended to other pathological cardiac conditions and warrants future study. Furthermore, these data demonstrate the critical role of IL-6 in HIMF-induced cardiac hypertrophy and fibrosis. Humanized anti-IL-6 receptor antibody, tocilizumab has been developed for the treatment of patients with rheumatoid arthritis. 33 A recent study based on a well-designed and innovative phase II clinical trial shows that IL-6 blockade by tocilizumab had beneficial effects on acute coronary syndrome. 34 In view of the current findings, IL-6 blockade by tocilizumab is potentially an alternative therapeutic strategy for the treatment of cardiac hypertrophy and HIMF-related heart diseases.
